creatine has been researched along with MELAS Syndrome in 10 studies
MELAS Syndrome: A mitochondrial disorder characterized by focal or generalized seizures, episodes of transient or persistent neurologic dysfunction resembling strokes, and ragged-red fibers on muscle biopsy. Affected individuals tend to be normal at birth through early childhood, then experience growth failure, episodic vomiting, and recurrent cerebral insults resulting in visual loss and hemiparesis. The cortical lesions tend to occur in the parietal and occipital lobes and are not associated with vascular occlusion. VASCULAR HEADACHE is frequently associated and the disorder tends to be familial. (From Joynt, Clinical Neurology, 1992, Ch56, p117)
| Excerpt | Relevance | Reference |
|---|---|---|
| "An 18-year-old male patient with MELAS phenotype and 2 previous episodes of cerebral stroke, recurrent seizures and nephropathy, was treated with creatine monohydrate after the acute onset of psychomental regression and changing states of somnolence and aggressive and agitated behaviour." | 7.71 | Effects of oral creatine supplementation in a patient with MELAS phenotype and associated nephropathy. ( Barisic, N; Bernert, G; Bittner, RE; Gruber, S; Ipsiroglu, O; Moser, E; Müller, T; Prayer, D; Stöckler-Ipsiroglu, S; Stromberger, C, 2002) |
| " Mutation carriers included 45 patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS); 11 participants who would develop the MELAS syndrome during follow-up (converters); and 79 participants who would not develop the MELAS syndrome during follow-up (nonconverters)." | 3.80 | Cerebral metabolic abnormalities in A3243G mitochondrial DNA mutation carriers. ( De Vivo, D; DiMauro, S; Engelstad, KM; Hinton, V; Kaufmann, P; Mao, X; Shungu, D; Weiduschat, N, 2014) |
| "An 18-year-old male patient with MELAS phenotype and 2 previous episodes of cerebral stroke, recurrent seizures and nephropathy, was treated with creatine monohydrate after the acute onset of psychomental regression and changing states of somnolence and aggressive and agitated behaviour." | 3.71 | Effects of oral creatine supplementation in a patient with MELAS phenotype and associated nephropathy. ( Barisic, N; Bernert, G; Bittner, RE; Gruber, S; Ipsiroglu, O; Moser, E; Müller, T; Prayer, D; Stöckler-Ipsiroglu, S; Stromberger, C, 2002) |
| "1H magnetic resonance spectroscopy (MRS) of the brain and (31)P MRS and saturation transfer of resting skeletal muscle were used to investigate intracellular metabolites and fluxes through the creatine kinase (CK) reaction in a patient with the syndrome of mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS)." | 3.71 | Application of NMR spectroscopy to monitoring MELAS treatment: a case report. ( Hilbich, T; Kurlemann, G; Möller, HE; Schuierer, G; Wiedermann, D, 2002) |
| "To our knowledge, this is the first study to assess the response to treatment of a MELAS strokelike episode and the first to show an increase in the lactate-creatine ratio in a brain region that was associated with a clinical abnormality, even though it appeared normal on magnetic resonance imaging." | 3.70 | Magnetic resonance spectroscopy: use in monitoring MELAS treatment. ( Kaplan, GP; Kingsley, PB; Lustbader, D; O'Shea, M; Pavlakis, SG; Stacpoole, PW, 1998) |
| "Localized brain proton MR spectra were acquired from patients with different mitochondrial encephalomyopathies (myoclonus epilepsy with ragged-red fibers [MERRF], Kearns-Sayre syndrome [KSS], and mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes [MELAS])." | 3.68 | Proton MR spectroscopic characterization of differences in regional brain metabolic abnormalities in mitochondrial encephalomyopathies. ( Andermann, F; Arnold, DL; Karpati, G; Mathews, PM; Silver, K, 1993) |
| "The mitochondrial encephalomyopathies are chronic progressive disorders affecting predominantly the neuromuscular system." | 1.32 | Effectiveness of creatine monohydrate in mitochondrial encephalomyopathies. ( Hanefeld, FA; Hobbiebrunken, E; Komura, K; Wilichowski, EK, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, R | 1 |
| Hu, B | 1 |
| Sun, C | 1 |
| Geng, D | 1 |
| Lin, J | 1 |
| Li, Y | 1 |
| Weiduschat, N | 1 |
| Kaufmann, P | 1 |
| Mao, X | 1 |
| Engelstad, KM | 1 |
| Hinton, V | 1 |
| DiMauro, S | 1 |
| De Vivo, D | 1 |
| Shungu, D | 1 |
| Coman, D | 1 |
| Yaplito-Lee, J | 1 |
| Boneh, A | 1 |
| Barisic, N | 1 |
| Bernert, G | 1 |
| Ipsiroglu, O | 1 |
| Stromberger, C | 1 |
| Müller, T | 1 |
| Gruber, S | 1 |
| Prayer, D | 1 |
| Moser, E | 1 |
| Bittner, RE | 1 |
| Stöckler-Ipsiroglu, S | 1 |
| Komura, K | 1 |
| Hobbiebrunken, E | 1 |
| Wilichowski, EK | 1 |
| Hanefeld, FA | 1 |
| Hagenfeldt, L | 1 |
| von Döbeln, U | 1 |
| Solders, G | 1 |
| Kaijser, L | 1 |
| Mathews, PM | 1 |
| Andermann, F | 1 |
| Silver, K | 1 |
| Karpati, G | 1 |
| Arnold, DL | 1 |
| Pavlakis, SG | 1 |
| Kingsley, PB | 1 |
| Kaplan, GP | 1 |
| Stacpoole, PW | 1 |
| O'Shea, M | 1 |
| Lustbader, D | 1 |
| Kim, HS | 1 |
| Kim, DI | 1 |
| Lee, BI | 1 |
| Jeong, EK | 1 |
| Choi, C | 1 |
| Lee, JD | 1 |
| Yoon, PH | 1 |
| Kim, EJ | 1 |
| Kim, SH | 1 |
| Yoon, YK | 1 |
| Möller, HE | 1 |
| Wiedermann, D | 1 |
| Kurlemann, G | 1 |
| Hilbich, T | 1 |
| Schuierer, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Mitochondrial Encephalomyopathies and Mental Retardation: Investigations of Clinical Syndromes Associated With MtDNA Point Mutations[NCT01532791] | 300 participants (Anticipated) | Observational | 2004-07-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for creatine and MELAS Syndrome
| Article | Year |
|---|---|
New indications and controversies in arginine therapy.
Topics: Acidosis, Lactic; Amino Acid Metabolism, Inborn Errors; Arginine; Central Nervous System; Creatine; | 2008 |
9 other studies available for creatine and MELAS Syndrome
| Article | Year |
|---|---|
Metabolic abnormality in acute stroke-like lesion and its relationship with focal cerebral blood flow in patients with MELAS: Evidence from proton MR spectroscopy and arterial spin labeling.
Topics: Adolescent; Adult; Aspartic Acid; Brain; Case-Control Studies; Choline; Creatine; Female; Glutamic A | 2021 |
Cerebral metabolic abnormalities in A3243G mitochondrial DNA mutation carriers.
Topics: Acidosis, Lactic; Adult; Aged; Aspartic Acid; Cerebral Cortex; Choline; Creatine; DNA, Mitochondrial | 2014 |
Effects of oral creatine supplementation in a patient with MELAS phenotype and associated nephropathy.
Topics: Administration, Oral; Adolescent; Creatine; Dietary Supplements; Humans; Kidney Diseases; Male; MELA | 2002 |
Effectiveness of creatine monohydrate in mitochondrial encephalomyopathies.
Topics: Adolescent; Adult; Child; Creatine; Exercise Test; Female; Humans; Lactic Acid; Male; MELAS Syndrome | 2003 |
Creatine treatment in MELAS.
Topics: Administration, Oral; Adult; Brain; Creatine; Electroencephalography; Humans; Magnetic Resonance Ima | 1994 |
Proton MR spectroscopic characterization of differences in regional brain metabolic abnormalities in mitochondrial encephalomyopathies.
Topics: Aspartic Acid; Brain; Choline; Creatine; Humans; Kearns-Sayre Syndrome; Lactates; Lactic Acid; Magne | 1993 |
Magnetic resonance spectroscopy: use in monitoring MELAS treatment.
Topics: Adult; Brain; Cerebrovascular Disorders; Creatine; Dichloroacetic Acid; Female; Humans; Lactic Acid; | 1998 |
Diffusion-weighted image and MR spectroscopic analysis of a case of MELAS with repeated attacks.
Topics: Adolescent; Aspartic Acid; Brain; Creatine; Diffusion; Female; Humans; Magnetic Resonance Imaging; M | 2001 |
Application of NMR spectroscopy to monitoring MELAS treatment: a case report.
Topics: Adolescent; Aspartic Acid; Brain; Creatine; Female; Glutamic Acid; Humans; Inositol; Lactic Acid; Ma | 2002 |